A detailed history of Gilder Gagnon Howe & CO LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 274,748 shares of BNTX stock, worth $21.6 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares
274,748
Previous 359,708 23.62%
Holding current value
$21.6 Million
Previous $38 Million 33.24%
% of portfolio
0.33%
Previous 0.53%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$88.96 - $112.35 $7.56 Million - $9.55 Million
-84,960 Reduced 23.62%
274,748 $25.3 Million
Q4 2023

Feb 14, 2024

SELL
$90.91 - $112.75 $4.24 Million - $5.26 Million
-46,685 Reduced 11.49%
359,708 $38 Million
Q3 2023

Nov 14, 2023

SELL
$98.5 - $125.08 $5.5 Million - $6.99 Million
-55,885 Reduced 12.09%
406,393 $44.2 Million
Q2 2023

Aug 14, 2023

BUY
$102.58 - $129.66 $658,768 - $832,676
6,422 Added 1.41%
462,278 $49.9 Million
Q1 2023

May 15, 2023

SELL
$122.57 - $153.67 $314,269 - $394,009
-2,564 Reduced 0.56%
455,856 $56.8 Million
Q4 2022

Feb 14, 2023

BUY
$118.43 - $186.05 $4.79 Million - $7.53 Million
40,478 Added 9.69%
458,420 $68.9 Million
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $18.6 Million - $26.7 Million
145,658 Added 53.49%
417,942 $56.4 Million
Q2 2022

Aug 15, 2022

SELL
$123.25 - $186.24 $3.43 Million - $5.18 Million
-27,800 Reduced 9.26%
272,284 $40.6 Million
Q1 2022

May 16, 2022

SELL
$126.25 - $231.85 $7.19 Million - $13.2 Million
-56,990 Reduced 15.96%
300,084 $51.2 Million
Q4 2021

Feb 14, 2022

BUY
$216.64 - $362.52 $66.3 Million - $111 Million
305,931 Added 598.19%
357,074 $92.1 Million
Q3 2021

Nov 15, 2021

BUY
$205.93 - $447.23 $2.92 Million - $6.34 Million
14,178 Added 38.36%
51,143 $14 Million
Q2 2021

Aug 16, 2021

BUY
$113.32 - $241.49 $4.19 Million - $8.93 Million
36,965 New
36,965 $8.28 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $19.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.